Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
3SBio announced a new investment partnership, called...
Shanghai Pharma is seeking to acquire a mid-sized US or...
Shanghai Duyiwei Biotechnology, a subsidiary of Gansu...
3SBio will form a $20 million JV with DaVita Inc., a...
Abcam will pay $170 million to buy Epitomics, a US mAb...
3SBio received permission from the SFDA to conduct the...
China plans to spend $11.8 billion to increase biopharma...
3SBio filed an Investigational New Drug (IND) application...
Hangzhou Tigermed Consulting, a clinical-stage CRO,...
3SBio, a China biotech, received an offer to take the...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
